ArticleRegenerative biomaterials2022
Regenerative cerium oxide nanozymes alleviate oxidative stress for efficient dry eye disease treatment.
Article in Regenerative biomaterials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Self-Propelled HPB@Lip@AB Nanomotors Ameliorate Dry Eye Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanosized Cerium Phosphate: Synthesis Methods, Morphology, and Potential Applications in Biomedicine.Biomedicines · 2026Review
- Toxicity Validation of Cerium Oxide Nanoparticles and Mechanism of Action in the Treatment of Cerebral Ischemia-reperfusion Injury.Biological trace element research · 2026Article
- Enhanced ocular delivery of tacrolimus via cationic nanoliposomes: Mitigating inflammation and rebalancing Th17/Treg responses in dry eye disease.Materials today. Bio · 2026Article
- Oxidative Stress in Dry Eye Disease: Molecular Mechanisms and Emerging Therapeutic Strategies.Biomolecules · 2026Review
- Palladium nanozyme loaded metal-organic framework eyedrops alleviate oxidative stress for dry eye treatment.Journal of nanobiotechnology · 2026Article
- Engineering Strategies of Colloidal Drug Delivery Systems, a Rising Star in Ocular Neovascular Diseases.Molecules (Basel, Switzerland) · 2026Review
- Transcriptomics and Network Pharmacology Reveal Anti-Inflammatory and Anti-Oxidative Stress Mechanisms of Qingxuan Runmu Yin in Dry Eye Disease.Journal of inflammation research · 2026Article
- Photothermal and cascade ROS generative multilayer as intraocular lens surface coating for effective posterior capsular opacification inhibition.Regenerative biomaterials · 2026Article
- Biodistribution and Toxicological Impact Assessment of Cerium Dioxide Nanoparticles in Murine Models: A Systematic Review of In Vivo and Ex Vivo Studies.Pharmaceutics · 2025Review
- Review
- Dry Eye Disease: Oxidative Stress on Ocular Surface and Cutting-Edge Antioxidants.Global challenges (Hoboken, NJ) · 2025Review
- Conditioned media of stem cells from human exfoliated deciduous teeth contain factors related to extracellular matrix organization and promotes corneal epithelial wound healing.Regenerative therapy · 2025Article
- Nanozymes for Treating Ocular Diseases.Advanced healthcare materials · 2025Review
- Matrix metalloproteinase-2 and pH-responsive drug eluting multilayer as intraocular lens coating to improve the posterior capsule opacification inhibition.Regenerative biomaterials · 2025Article
- Ocular bio-lubricating materials: from lubrication mechanism to dry eye syndrome treatment.Regenerative biomaterials · 2025Review
- Tailoring metal oxide nanozymes for biomedical applications: trends, limitations, and perceptions.Analytical and bioanalytical chemistry · 2024Review
- Nanomedicines for Dry Eye Syndrome: Targeting Oxidative Stress with Modern Nanomaterial Strategies.Molecules (Basel, Switzerland) · 2024Review
- Recent Advances in Nanotechnology for the Treatment of Dry Eye Disease.Nanomaterials (Basel, Switzerland) · 2024Review
- A lipid/PLGA nanocomplex to reshape tumor immune microenvironment for colon cancer therapy.Regenerative biomaterials · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease (DED) is the most common eye disease in ophthalmic consultation except for refractive errors. Therefore, an exploration of valid and alternative therapeutic interventions is essential to feed the urgent medical need. It has been demonstrated that oxidative stress causes multiple adverse effects in the pathogenesis of DED, thence alleviating oxidative stress is an effective therapeutic strategy for the DED treatment. Herein, we developed a cerium oxide nanozyme combined with branched poly(ethylene imine)-graft-poly(ethylene glycol) (bPEI-g-PEG). Owing to its stable hydrophilic chains on the surface reducing the cytotoxicity and loads of amines groups that be combined with cerium ions through coordination bonds, the modified nanozymes (referred to as CNP@bPEI-g-PEG) are water soluble and highly biocompatible. Meanwhile, due to its excellent antioxidant activity, CNP@bPEI-g-PEG nanozymes can mimic the activity of superoxide dismutase and catalase to scavenge intracellular reactive oxygen species (ROS). Experimental studies firmly demonstrated that the modified nanozymes were auto-regenerative and more active in scavenging excessive ROS and alleviating oxidative stress by cerium-element valence state recycling, recovering the morphology of corneal, conjunctival epithelium and the number of goblet cells. The advanced combination may offer a superior therapeutic strategy to deal with oxidative stress for effective treatment of DED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.